Zumutor has successfully filed 6 PCT and several provisional applications encompassing the technology platform and products. Our Antibody display technology platforms and products thereof are adequately covered for future licensing. In addition, our platforms are innovative, and have therefore resulted in multiple applications. All products from our pipeline will be considered as New Biological Entities and new IP applications will be filed. Our aim is to create a powerful IP portfolio around our technologies and products for licensing and/or collaborations.